drug · protein
aflibercept biosimilar
Marketedupdated 6mo agoby Sam Chun Dang Pharm Co Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7Protein drug with a maximum clinical stage of Approval (across all indications), with 16 approved and 39 investigational indications.
indications
investigational
Diabetic Macular Edema
targets
Placenta growth factorVascular endothelial growth factor A, long form
all catalysts(3)
Trials studying aflibercept biosimilar
- phase3Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
- phase3Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
- phase3A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
News(10)
- Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilienceAstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.biopharma_dive · 13d ago
- Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deckRegeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…biospace · 16d ago
- EyePoint will halve workforce, end pivotal wet AMD trials early following second failEyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shiftin…biospace · 27d ago
- This week in charts: Kodiak’s big comeback and Hengrui’s dealmakingThe latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.biopharma_dive · 1mo ago
- Lilly, Foghorn part ways; Wave’s FDA-approved plansThe pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.biopharma_dive · 1mo ago
- Kodiak skyrockets on positive study data for 2 eye drugsThe Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.biopharma_dive · 1mo ago
- Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitorKodiak Sciences appears to have an Eylea successor on its hands. The Silicon Valley biotech said its experimental drug Zenkuda performed as well as Eylea in a progressive eye disease known as wet a…endpoints · 1mo ago
- Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trialKodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.biospace · 1mo ago
- STAT+: AbbVie wins FDA nod for Parkinson’s pillThe FDA has approved AbbVie’s once-daily Parkinson’s pill for sales, based on a late-stage study that showed the drug helped improve symptoms.stat · 1mo ago
- Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3Two of Kodiak Sciences’ drug candidates have matched aflibercept in a phase 3 clinical trial, positioning the biotech to seek FDA approval of one of the eye disease assets this year.fiercebiotech · 1mo ago
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that